NASDAQ:RNA Avidity Biosciences - RNA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.35 -1.45 (-8.63%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$15.07▼$16.2150-Day Range$16.80▼$25.6552-Week Range$9.83▼$25.74Volume3.50 million shsAverage Volume970,769 shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$44.60 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Avidity Biosciences MarketRank™ ForecastAnalyst RatingBuy3.20 Rating ScoreUpside/Downside184.0% Upside$43.60 Price TargetShort InterestBearish12.27% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.11Based on 12 Articles This WeekInsider TradingSelling Shares$556,584 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.63) to ($3.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.72 out of 5 starsMedical Sector841st out of 1,004 stocksPharmaceutical Preparations Industry411th out of 489 stocks 3.6 Analyst's Opinion Consensus RatingAvidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.60, Avidity Biosciences has a forecasted upside of 184.0% from its current price of $15.35.Amount of Analyst CoverageAvidity Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.27% of the outstanding shares of Avidity Biosciences have been sold short.Short Interest Ratio / Days to CoverAvidity Biosciences has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Avidity Biosciences has recently increased by 4.57%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAvidity Biosciences does not currently pay a dividend.Dividend GrowthAvidity Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RNA. Previous Next 2.8 News and Social Media Coverage News SentimentAvidity Biosciences has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Avidity Biosciences this week, compared to 2 articles on an average week.Search Interest25 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 39% compared to the previous 30 days.MarketBeat Follows8 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $556,584.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of Avidity Biosciences is held by insiders. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.63) to ($3.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avidity Biosciences is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avidity Biosciences is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvidity Biosciences has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avidity Biosciences (NASDAQ:RNA) StockAvidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Read More Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Stock News HeadlinesMarch 31, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Avidity BiosciencesMarch 31, 2023 | markets.businessinsider.comChardan Capital Remains a Buy on Avidity Biosciences (RNA)April 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 30, 2023 | finance.yahoo.comAvidity Bio Crashes 17% After 'Rarer Than Rare' Event Sidelines Key StudyMarch 30, 2023 | msn.comAvidity slumps ~15% after plans to conclude muscle disorder trial amid FDA partial holdMarch 30, 2023 | finance.yahoo.comAvidity Bio Crashes 15% After 'Rarer Than Rare' Event Sidelines Key StudyMarch 30, 2023 | finance.yahoo.comWhy Avidity Biosciences Shares Are Sliding TodayMarch 30, 2023 | finance.yahoo.comAvidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual MeetingApril 1, 2023 | Vantage Point (Ad)Did You See These Trend Reversals?Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. March 30, 2023 | finance.yahoo.comAvidity Bio Crashes 28% After 'Rarer Than Rare' Event Sidelines Key StudyMarch 24, 2023 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Shares Down 3.6% March 13, 2023 | finance.yahoo.comAvidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific ConferenceMarch 11, 2023 | seekingalpha.comAvidity Biosciences: Helping Deliver Oligonucleotides Outside Liver CellsMarch 1, 2023 | markets.businessinsider.comAvidity Biosciences (RNA) Receives a Buy from Credit SuisseMarch 1, 2023 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent HighlightsMarch 1, 2023 | finance.yahoo.comAvidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent HighlightsMarch 1, 2023 | finance.yahoo.comAvidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue EstimatesFebruary 27, 2023 | finance.yahoo.comAnalyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades StockFebruary 27, 2023 | finance.yahoo.comAvidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ PlatformFebruary 23, 2023 | finance.yahoo.comAvidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic LeaderFebruary 14, 2023 | markets.businessinsider.comAvidity's AOC 1020 Gets FDA Orphan Drug Designation For Muscular Dystrophy TreatmentFebruary 14, 2023 | marketwatch.comAvidity Biosciences Gets FDA Orphan Designation for AOC 1020 >RNAFebruary 14, 2023 | finance.yahoo.comAvidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular DystrophyFebruary 7, 2023 | finance.yahoo.comAvidity Biosciences to Participate in Upcoming Investor ConferenceFebruary 2, 2023 | finance.yahoo.comThe one-year returns have been notable for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasingJanuary 18, 2023 | msn.comAvidity's therapy for rare muscle disorder gets FDA fast track statusJanuary 18, 2023 | finance.yahoo.comAvidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular DystrophySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RNA Company Calendar Last Earnings11/09/2021Today3/31/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RNA CUSIPN/A CIK1574111 Webwww.aviditybiosciences.com Phone858-401-7900FaxN/AEmployees125Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.60 High Stock Price Forecast$71.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+190.6%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-173,990,000.00 Net Margins-1,886.33% Pretax Margin-1,886.33% Return on Equity-40.82% Return on Assets-36.41% Debt Debt-to-Equity RatioN/A Current Ratio12.00 Quick Ratio12.00 Sales & Book Value Annual Sales$9.22 million Price / Sales117.89 Cash FlowN/A Price / Cash FlowN/A Book Value$8.29 per share Price / Book1.85Miscellaneous Outstanding Shares70,810,000Free Float66,135,000Market Cap$1.09 billion OptionableNot Optionable BetaN/A Key ExecutivesDr. Troy Edward Wilson J.D. (Age 53)Ph.D., Co-Founder & Chairman Comp: $65kMs. Sarah Boyce (Age 50)Pres, CEO & Director Comp: $1MMr. Michael F. MacLean (Age 56)Chief Financial & Bus. Officer Comp: $650.38kDr. W. Michael Flanagan Ph.D. (Age 60)Chief Technical Officer Comp: $1MDr. Arthur A. Levin Ph.D. (Age 68)Chief Scientific Officer Comp: $662.86kProf. Mark E. DavisScientific Founder, Member of Scientific Advisory Board and Member of Board of Mang.sDr. Frank McCormick Ph.D. (Age 72)Scientific Founder & Member of Scientific Advisory Board Ms. Kathleen GallagherSr. VP of Corp. Communications & Investor RelationsDr. John W. Wallen III (Age 64)VP of Intellectual Property, Gen. Counsel & Sec. Ms. Teresa McCarthyChief HR OfficerMore ExecutivesKey CompetitorsTravere TherapeuticsNASDAQ:TVTXDICE TherapeuticsNASDAQ:DICESyndax PharmaceuticalsNASDAQ:SNDXMorphicNASDAQ:MORFArvinasNASDAQ:ARVNView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCBought 2,469 shares on 3/23/2023Ownership: 0.040%Voya Investment Management LLCBought 24,866 shares on 2/28/2023Ownership: 0.082%NatixisBought 5,465 shares on 2/24/2023Ownership: 0.010%Alliancebernstein L.P.Bought 88,694 shares on 2/16/2023Ownership: 0.382%State of Wisconsin Investment BoardBought 2,261 shares on 2/15/2023Ownership: 0.071%View All Insider TransactionsView All Institutional Transactions RNA Stock - Frequently Asked Questions Should I buy or sell Avidity Biosciences stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RNA shares. View RNA analyst ratings or view top-rated stocks. What is Avidity Biosciences' stock price forecast for 2023? 5 brokerages have issued 1 year target prices for Avidity Biosciences' shares. Their RNA share price forecasts range from $27.00 to $71.00. On average, they predict the company's share price to reach $43.60 in the next year. This suggests a possible upside of 184.0% from the stock's current price. View analysts price targets for RNA or view top-rated stocks among Wall Street analysts. How have RNA shares performed in 2023? Avidity Biosciences' stock was trading at $22.19 at the start of the year. Since then, RNA stock has decreased by 30.8% and is now trading at $15.35. View the best growth stocks for 2023 here. When is Avidity Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our RNA earnings forecast. How were Avidity Biosciences' earnings last quarter? Avidity Biosciences, Inc. (NASDAQ:RNA) released its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.68) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.68). The biotechnology company earned $2.16 million during the quarter, compared to analyst estimates of $1.50 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 40.82% and a negative net margin of 1,886.33%. What ETFs hold Avidity Biosciences' stock? ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion mRNA ETF (MSGR), Direxion Moonshot Innovators ETF (MOON), Alger 35 ETF (ATFV), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Raymond James SB-1 Equity ETF (RYJ). What other stocks do shareholders of Avidity Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT). When did Avidity Biosciences IPO? (RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO. What is Avidity Biosciences' stock symbol? Avidity Biosciences trades on the NASDAQ under the ticker symbol "RNA." Who are Avidity Biosciences' major shareholders? Avidity Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (12.32%), RA Capital Management L.P. (10.02%), Cowen AND Company LLC (7.87%), Avidity Partners Management LP (6.01%), Avoro Capital Advisors LLC (3.76%) and Artisan Partners Limited Partnership (2.39%). Insiders that own company stock include Arthur A Levin, Rtw Investments, Lp and Sarah Boyce. View institutional ownership trends. How do I buy shares of Avidity Biosciences? Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avidity Biosciences' stock price today? One share of RNA stock can currently be purchased for approximately $15.35. How much money does Avidity Biosciences make? Avidity Biosciences (NASDAQ:RNA) has a market capitalization of $1.09 billion and generates $9.22 million in revenue each year. The biotechnology company earns $-173,990,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis. How many employees does Avidity Biosciences have? The company employs 125 workers across the globe. How can I contact Avidity Biosciences? Avidity Biosciences' mailing address is 10975 N. TORREY PINES RD. SUITE 150, LA JOLLA CA, 92037. The official website for the company is www.aviditybiosciences.com. The biotechnology company can be reached via phone at 858-401-7900 or via email at amy@juniper-point.com. This page (NASDAQ:RNA) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.